Targeting regulatory T cells

Christine Ménétrier-Caux, Tyler Curiel, Julien Faget, Manuarii Manuel, Christophe Caux, Weiping Zou

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations


Cancers express tumor-associated antigens that should elicit immune response to antagonize the tumor growth, but spontaneous immune rejection of established cancer is rare, suggesting an immunosuppressive environment hindering host antitumor immunity. Among the specific and active tumor-mediated mechanisms, CD4 +CD25 high T regulatory cells (Treg) are important mediators of active immune evasion in cancer. In this review, we will discuss Treg subpopulations and the mechanisms of their suppressive functions. Treg depletion improves endogenous antitumor immunity and the efficacy of active immunotherapy in animal models for cancer, suggesting that inhibiting Treg function could also improve the limited successes of human cancer immunotherapy. We will also discuss specific strategies for devising effective cancer immunotherapy targeting Treg.

Original languageEnglish (US)
Pages (from-to)15-28
Number of pages14
JournalTargeted Oncology
Issue number1
StatePublished - Mar 2012


  • Immunosuppression
  • Regulatory Tcells
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Targeting regulatory T cells'. Together they form a unique fingerprint.

Cite this